Objective: Historically, edge stenosis and late thrombosis limited the effectiveness of adjunctive endovascular brachytherapy (EVBT) for in-stent restenosis (ISR) after percutaneous transluminal angioplasty (PTA) and stenting. We evaluated an updated protocol of PTA and EVBT for ISR among patients with lower extremity occlusive disease.
Purported mechanisms of failure of percutaneous transluminal angioplasty (PTA) of lower extremity arterial occlusive disease include immediate elastic recoil, acute thrombosis, neointimal hyperplasia, and late vascular remodeling. 1, 2 Although PTA with stenting prevents elastic recoil and constrictive remodeling, in-stent restenosis (ISR), a consequence of neointimal hyperplasia, is a pervasive problem. 3 A wide array of strategies are currently available to address ISR, including drugcoated balloons (DCB), drug-eluting stents (DES), cutting balloon angioplasty, stent grafts, atherectomy, and surgical bypass. No one of these strategies has yet been proven to be the definitive treatment for ISR. 4 Endovascular brachytherapy (EVBT), or the local intraluminal application of radiation from beta or gamma sources to a target vessel, is another strategy that mitigates neointimal hyperplasia. 1, 5, 6 Numerous early efforts examining the effect of EVBT in the treatment of de novo lesions [7] [8] [9] and in the prevention of restenosis (prophylaxis) after PTA [10] [11] [12] [13] and PTA with stenting [14] [15] [16] [17] were limited by edge stenosis and late stent thrombosis. More recent reports have had more promising results. 18, 19 In this study, we retrospectively evaluate the effectiveness of adjunctive EVBT to sustain the patency of PTA treatment of ISR in the iliac, superficial femoral artery (SFA), and popliteal artery segments using an updated protocol for iridium 192 ( 192 Ir) gamma irradiation at a high dose rate. Key aspects of our revised protocol include a higher dose of radiation, an extension of the safety margin of radiation coverage proximal and distal to the injured area by at least 2 cm, and a customized The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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METHODS
Study population. This is a retrospective cohort review of PTA and adjunctive EVBT for ISR in the iliac, SFA, and popliteal artery segments performed at Brigham and Women's Hospital (Boston, Mass) between November 2004 and November 2012. This study was approved by the Institutional Review Board. Need for informed consent was waived.
Periprocedural and procedural details. The study included all patients in the Division of Vascular and Endovascular Surgery who underwent PTA and adjunctive EVBT for ISR in the iliac, SFA, and popliteal artery segments during the study period. All patients were treated in the standard manner of the practice of their vascular surgeon (M.T.M., E.C.G., and L.L.N.). Patients with recurrent symptoms or hemodynamically significant lesions ascribed to ISR identified by duplex imaging and associated with an ankle-brachial index (ABI) decrease $0.15 were preferentially treated with repeat PTA and adjunctive EVBT. Long-segment ($20 cm) stent occlusions were typically treated with surgical bypass.
If the combination of patient history, physical examination findings, and duplex ultrasound imaging was suggestive of ISR, the patient was referred to the radiation oncologist for evaluation, informed consent was obtained, and the brachytherapy suite was reserved in advance. The patient was made aware that the final decision to undertake brachytherapy would be contingent on the angiographic findings on the day of the planned treatment. An ISR lesion was distinguished from residual stenosis by comparing the confirmatory angiographic images to those from the original stenting procedure.
All procedures were undertaken in a collaborative fashion by a board-certified vascular surgeon and radiation oncologist. Procedures were performed under conscious sedation supplemented with local anesthesia to the arterial access site. Retrograde contralateral femoral access was used in most cases, although brachial access was used on several occasions involving ISR of the iliac arteries in patients with dense groin scarring.
After a diagnostic arteriogram was performed, a 6F guiding sheath was introduced, the patient was systemically anticoagulated with heparin, the ISR lesion was crossed with a wire, and PTA was performed within the area of ISR. Additional PTA was undertaken to treat edge stenosis or new lesions in adjacent arterial segments if deemed necessary by the treating vascular surgeon. Adjacent new lesions were occasionally stented, also at the discretion of the treating vascular surgeon.
Once an angiographically satisfactory result (residual stenosis #30% and no evidence of dissection) was obtained, the wire was removed and a blind-ended, 150-cm-long, 6F high-dose rate brachytherapy catheter was placed. All angioplasty images and anatomic landmarks were reviewed, followed by placement of a calibrated brachytherapy "dummy strand" within the brachytherapy catheter to assist in precise intravascular measurement. The catheter and dummy strand were advanced across the angioplastied segment until the tip was 2 to 3 cm distal to the distal margin of the angioplastied segment (Fig 1) . These 2-to 3-cm-long margins were used to address potential uncertainty in the exact position of the balloon and to allow for slight "watermelon seeding" and the tapering off of the radiation dose at the ends of the treatment zones. The sheath tip was withdrawn to the arterial segment proximal to the angioplastied segment to minimize the risk of sheath-induced thrombosis during the EVBT portion of the procedure.
Fluoroscopic images of the final position of the catheter and dummy strand were taken, and the length of the treatment was determined by the length of all angioplastied segments and the margins. Careful note was made of the largest balloon diameter deployed. The distance from the catheter for the 100% isodose line was determined to be the radius of the largest balloon plus 0.5 mm. The treatment depth of 0.5 mm beyond the radius of the largest PTA balloon was chosen to avoid overdosing smaller-than-average vessels and underdosing larger-than-average vessels and was based on normal clinical physics recommendations to be as specific as possible to the clinical target of radiation. The sheath and brachytherapy catheter were secured with sutures, an activated clotting time level >250 seconds was confirmed, and a heparin infusion of 500 units/hour was started via a peripheral intravenous catheter. The patient was transported to the EVBT suite on a stretcher by a nurse, and one-on-one nursing care was continued through the duration of the EVBT procedure.
EVBT was planned with a dedicated computerassisted treatment planning system and was performed with a remote afterloader with a high dose rate. In brief, the remote afterloader is a machine that houses a single high-activity 192 Ir isotope that is welded to a cable and driven by a computer to preset locations based on treatment planning for optimized amounts of time to deliver a safe and graphically optimized uniform radiation treatment to the clinical target of the vessel wall. A dose of 20 Gy was prescribed to give a treatment depth of 0.5 mm beyond the radius of the largest PTA balloon. The dose of 20 Gy was selected because of treatment failures in prior published trials using 14 Gy. 8, 16, 17, 20 Furthermore, 20 Gy has previously been used with demonstrated safety and efficacy in intracoronary brachytherapy. 21 The 192 Ir source was delivered in a stepwise manner to cover the entire angioplastied segment and an additional safety margin of 2 to 3 cm proximally and distally to avoid edge stenosis and geographic miss. At the conclusion of EVBT, protamine (50 mg) was administered, the patient was brought to the angiography recovery room, the sheath and brachytherapy catheter were removed, and hemostasis at the access site was achieved with manual pressure. Depending on the time of day, the patient was discharged home or observed overnight in the hospital. Patients were treated with clopidogrel and aspirin (either 81 or 325 mg) indefinitely, unless contraindicated.
Patients were monitored by duplex ultrasound surveillance of the treated arteries at 1, 3, 6, 9, 12, and 18 months and then yearly thereafter. Bilateral ABIs were assessed with each duplex ultrasound study. Recurrent critical stenosis (defined as $75% or a duplex velocity ratio >3.5) after EVBT was typically addressed by confirmatory angiography and additional percutaneous or open surgical treatment as deemed appropriate by the treating vascular surgeon.
Variables and end points. We collected data on patient demographics, comorbidities, medications, details of the original stenting procedure, all subsequent reinterventions before EVBT, and the EVBT treatment procedures. Chronic kidney disease was defined as preprocedure serum creatinine $2.0 mg/dL. Restenosis was defined as any stenosis within the irradiated area that had a The lesion is crossed with a wire, and balloon angioplasty is performed. C, A blind-ended brachytherapy and calibrated "dummy strand" for EVBT treatment planning are then placed across the angioplastied segment. The dummy strand has 1-cm radiopaque calibration markers and extends at least 2 cm beyond the angioplastied segment margins proximally and distally.
luminal narrowing of $50% on duplex ultrasound imaging. The duplex report typically documents the location of the stent margins in the artery and the location of the ISR lesion relative to the stent margins. A velocity ratio (Vr) was calculated from the peak systolic velocity within the stent to the peak systolic velocity of a more proximal and adjacent disease-free arterial segment. In our vascular laboratory, a Vr of <2.0 is considered <50% stenosis, a Vr of 2.0 to 3.5 is considered a 50% to 75% stenosis, and a Vr >3.5 is considered $75% stenosis. Absence of flow on duplex ultrasound imaging was graded as a stent occlusion.
Primary patency after EVBT was defined as freedom from restenosis or any repeat revascularization. Assisted primary patency after EVBT was defined as patency after reintervention for recurrent ISR, and secondary patency after EVBT was defined as patency after recanalization of an occluded stent. 22 Early thrombotic occlusion was total occlusion of a vessel from thrombus formation #30 days of EVBT. Late thrombotic occlusion was total occlusion after 30 or more days after EVBT. The primary end point was stent patency (primary, assisted primary, and secondary) assessed at 6 months, 1 year, and 2 years after EVBT. Secondary end points were early and late thrombotic occlusion.
Statistical analysis. Results are reported as mean 6 standard deviation, median with range, or percentages. Patency data were estimated using the Kaplan-Meier method and compared with the log-rank test. SAS 9.3 software (SAS Institute Inc, Cary, NC) was used for all statistical analyses. Table I .
Original stenting procedures. Twenty-seven patients (77%) underwent original stent placement for disabling claudication; the rest of the patients (19.1%) were treated for critical limb ischemia (CLI). A total of 55 stents were placed in the common iliac artery (n ¼ 2), external iliac artery (n ¼ 9), SFA (n ¼ 36), popliteal artery (n ¼ 2), and combined SFA and popliteal artery segments (n ¼ 7). Both common iliac artery stents were bare-metal balloon-expandable. External iliac stents were baremetal balloon-expandable (n ¼ 4) or bare-metal selfexpanding nitinol. All femoropopliteal artery segment stents were bare-metal self-expanding nitinol. No DES or stent grafts were used. Before the original stent placement, the mean ABI was 0.66 6 0.18 (range, 0.37-1.09).
Pre-EVBT interventions for ISR. Twelve patients (28.6%) underwent one percutaneous intervention for ISR before undergoing EVBT. Of these, 7 had undergone PTA alone, 3 had undergone PTA of the ISR lesion and additional stent placement in an adjacent or nonadjacent arterial segment, 1 had undergone thrombectomy of a thrombosed stent, and 1 had undergone laser atherectomy and PTA of an occluded stent. Three patients had undergone a second percutaneous intervention before EVBT: 1 repeat PTA of the recurrent ISR, 1 PTA with stent placement in a nonadjacent arterial segment, and 1 PTA and repeat stenting (stent within a stent).
Index PTA and adjunctive EVBT procedures. Characteristics of patients at the time of EVBT, stratified by the location of the ISR lesion, are summarized in Table II . In the cohort as a whole, 25 patients (71.4%) had symptoms at the time of EVBT, consisting of disabling claudication in 21 (60%) and CLI in four (11.4%). Asymptomatic ISR was identified on surveillance duplex ultrasound imaging in 16 patients (45.7%). The symptom status of one patient was not documented. No patients progressed from claudication at the time of the original stent placement to CLI at the time of EVBT, although two patients did have a one-vessel decrease in the number of patent tibial vessels during this period. Conversely, one patient with CLI at the time of stent placement had symptoms limited to claudication at the time of EVBT.
The median time to EVBT after stent placement was 550 days (range 151-2362 days). No stent fractures or stent occlusions were observed. Thirteen (37.1%) patients underwent additional stent placement at time of EVBT for edge stenosis or critical stenosis in other arterial segments. Mean treated length was 23.5 6 12.3 cm (range, 3-49 cm), mean treatment depth was 3.5 6 0.7 mm (range, 3-5.5 mm), and mean duration of treatment was 16.1 6 9.6 minutes (range, 3.5-45 minutes). After EVBT, 34 patients (81.0%) were discharged on both clopidogrel and aspirin, 3 patients (7.1%) on clopidogrel alone, and 1 (2.4%) on aspirin alone. Of the 34 patients for whom follow-up medication data were available 1 year after EVBT, 26 (76.4%) were still taking clopidogrel.
Outcomes. The technical success rate of EVBT was 97.6%; in one patient, the EVBT portion of the procedure was aborted given kinking of the EVBT catheter on the aortic bifurcation. Mean follow-up time after EVBT was 706.3 6 543.7 days (range, 1-2262 days). Among patients with claudication at the time of EVBT, symptoms resolved in 18 (85%) for the duration of their follow-up. Two patients had initial improvement, followed by recurrence of claudication (at 1 month and 34 months) that was associated with early occlusion in one patient and recurrent ISR in the other. The remaining patient had recurrent symptoms after 1 year despite patent stents. Of the four patients with CLI at the time of EVBT, the foot wound healed in one patient, rest pain resolved in one patient, one died the day after EVBT, and one (as mentioned above) did not undergo EVBT because of catheter kinking. A post-EVBT ABI was obtained for all but one patient. There was an overall mean ipsilateral ABI increase of 0.14 6 0.23 (range, À0.21 to 0.84). Primary, assisted primary, and secondary stent patency are shown Fig 2 and reported in Table III .
There were eight instances of recurrent ISR of 50% to 99% after EVBT, half of which occurred in iliac stents and half in femoropopliteal stents. The median time to recurrent stenosis after EVBT was 405 days (range, 57-909 days). In four instances, the recurrent ISR was limited to the stent; in four others, the recurrence was not within the stent but within the irradiated segment. PTA and EVBT were repeated in six of these eight cases, and no intervention was undertaken in the remaining two. In all eight 8 cases, assisted primary patency was preserved for the duration of the follow-up period. Early thrombotic occlusion occurred in two patients (4.9%) after EVBT. In the first patient, the occlusion occurred 1 day after EVBT. Repeat angiography confirmed complete occlusion of the SFA stents and thrombus at the anterior tibial artery takeoff. Percutaneous mechanical thrombectomy and catheterdirected thrombolysis successfully re-established tibial patency, although clearance of thrombus from the SFA stents was incomplete. The patient's rest pain resolved, and further revascularization was deferred. In the second patient, the occlusion was detected on the first surveillance duplex study performed 26 days after EVBT. Because the patient's claudication symptoms were not disabling, no intervention was performed.
Late thrombotic occlusion after EVBT occurred in five patients (11.9%) at a median 669 days (range, Table III . There were no instances of a standard error >10%. 365-1128 days) after EVBT. Three patients underwent open surgical revascularization (1 aortobifemoral bypass, 1 femoropopliteal bypass, and 1 femorotibial bypass); one of these patients later required a below-knee amputation after the bypass graft also failed. One patient found to have a thrombosed SFA stent on surveillance duplex ultrasound imaging was only mildly symptomatic, and no revascularization was attempted. The final patient underwent open thrombectomy of thrombosed iliac and SFA stents, which remained patent for the remainder of his subsequent follow-up. Only three of five patients who had late occlusions after EVBT remained on dual-antiplatelet therapy at the time of their thrombotic event. Of the eight patients with recurrent stenosis after EVBT, two (25%) had had a single reintervention and one (12.5%) patient had had two reinterventions for ISR before EVBT. None of the patients with early or late occlusions after EVBT had had reinterventions for ISR before EVBT. There was one death, which occurred the day after EVBT and was believed to be secondary to an acute coronary event.
DISCUSSION
We present a retrospective analysis of the early and midterm results of PTA and adjunctive EVBT using 192 Ir gamma radiation at a high dose rate for treatment of iliac or femoropopliteal ISR from a single-center cohort.
Technical success was achieved in 97.6% of cases. Primary patency rates at 1 and 2 years were encouraging, at 75.4% and 63.7%, respectively, and no patient had a worsening of lower extremity symptoms. Late thrombosis occurred in 11.9% of patients.
Although the association of external-beam radiation and accelerated atherosclerosis is well-documented, 23 small to moderate doses of intraluminal ionizing radiation have been shown to attenuate restenosis after vascular injury. 24 Potential mechanisms of this beneficial effect include mitigation of collagen synthesis, suppression of monocyte/macrophage activity, and decrement or delay of smooth muscle cell proliferation. 25 Magnetic resonance imaging of femoropopliteal arteries after PTA and PTAþEVBT demonstrated that EVBT does not have a short-term effect on remodeling arteries after angioplasty, but there is delayed healing and resolution of dissection after PTAþEVBT and continued lumen expansion at 3 months relative to PTA alone. 26 Swine studies of EVBT demonstrated that late expansion may also result from vessel wall weakness secondary to localized radiation-induced vasculitis. 27 In the peripheral arterial tree, EVBT has been used to treat de novo, restenosis, and ISR lesions. 28 Prior studies of EVBT for prophylaxis or treatment of ISR with EVBT are compared in were hampered by low enrollment and ultimately halted before completion. 29 Two more recent studies investigating the role of EVBT for ISR for infrainguinal arterial occlusive disease have shown more promising results. 18, 19 Our EVBT protocol differs from prior applications of EVBT using gamma irradiation to treat or prevent lower extremity ISR [14] [15] [16] [17] 30 in several important regards. We administered a higher radiation dose, used longer "safety margins" of radiation coverage beyond the injured segment to decrease geographic miss and edge stenosis, and used a customized treatment depth. We favor our technique over other protocols that use balloon delivery of liquid beta-emitters, such as rhenium 188, 19 given the risk of radiation contamination in the event of balloon rupture. Furthermore, neither strontium 90 18 nor rhenium 188 used in the most recent published studies are currently available in the United States.
In our study, ISR was diagnosed by duplex ultrasound studies. There is currently no consensus on standard duplex ultrasound criteria for quantifying the degree of ISR, which is reflected in the wide range of values found in the literature. Commonly used velocity criteria have been adopted from studies of de novo femoropopliteal lesions and from stenotic vein grafts. 31, 32 However, stent implantation decreases vessel compliance and thus elevates velocity relative to the unstented artery. 33 On one end of the spectrum, Baril et al 34 demonstrated
that a Vr of 1.5 correlated with $50% ISR in the SFA with of customized criteria from our own vascular laboratory, we used a Vr 2.0 for 50% ISR, which is a more conservative (ie, more "strict") criterion than that used in either of these studies. Our study offers another potential strategy for the treatment of femoropopliteal ISR, a condition for which no single strategy has to date demonstrated superiority. Like prior reports of EVBT to treat ISR in the femoropopliteal segment, we defined patency as freedom from $50% restenosis. Our primary patency results in this segment are superior to many other techniques for treating SFA ISR, including repeat balloon angioplasty, cutting balloon angioplasty, cryoplasty, directional atherectomy, and laser atherectomy with stent grafting, and comparable with DES, DCB, and stent grafting. PACT observed a 1-year primary patency rate of 80.5%, which was improved from historical controls of patients with diabetes and femoropopliteal ISR (71.8%; P < .0001). 40 Finally, in a multicenter trial of 100 patients with SFA ISR randomized to stent grafting or PTA, primary patency at 1 year was of 28% in the PTA group vs 72% in the Viabahn (W. L. Gore & Associates, Newark, Del) group (P < .001). 41 A subgroup analysis showed patency in the femoropopliteal cohort did not differ significantly from patency in the entire cohort overall (data not shown), suggesting that patency in the iliac subgroup did not skew the overall results in a more favorable direction. Our study differs from the Vienna-4 and Vienna-5 16, 17 trials in that we did not primarily focus on the use of brachytherapy for the prophylactic treatment of ISR. However, through routine stent surveillance, we did detect restenosis in a number of asymptomatic patients and elected to intervene in an effort to prevent stent occlusion. Although the relatively small number of such patients precludes a definitive comment on the validity of this strategy, we believe it may have contributed to the favorable assisted primary patency rates achieved in the current study. A known effect of EVBT is delayed re-endothelialization in the treated segment. In an magnetic resonance imaging study of femoropopliteal arteries that underwent PTA with or without EVBT, vessels that were treated with EVBT demonstrated decreased negative remodeling and an increase in lumen area but also had a persistently Refers to the total length of margins of radiation coverage proximal and distal to the angioplastied or stented area. disrupted vessel surface 3 months after treatment. 26 This is purported to be the etiology of late thrombosis 16, 42 and has led to the recommendation for at least 12 months of post-EVBT dual-antiplatelet therapy by some authors 43 and at least 24 months of dual anti-platelet therapy by others. 18 Prior reports of EVBT for ISR in the lower extremities observed variable rates of late thrombosis of 7% to 27%. 16, 17, 30, 42 We observed a 12% late thrombosis rate, and all events occurred after 1 year and despite dualantiplatelet therapy in most patients. It is possible that a more aggressive antiplatelet regimen would decrease the occurrences of late thrombosis. As mentioned, although radiation-induced vasculitis and vessel wall weakening are purported mechanisms of increased long-term lumen gain after PTAþEVBT, 27 we did not observe any instances of aneurysmal degeneration of treated arteries or any other gross vessel abnormalities in the three patients who underwent subsequent open revascularization.
Our study has multiple limitations, including its nonrandomized, retrospective nature, small cohort size, reduced follow-up at later time points, and lack of a control group. We do not have data on TransAtlantic Inter-Society Consensus criteria of the original lesions and, hence, cannot comment on the contribution of this or other anatomic factors to the development of ISR. Bossi et al 44 observed a correlation between ISR lesion type and repeat target lesion revascularization after balloon angioplasty in the coronary arteries, but Werner et al 19 found that ISR type in the femoropopliteal segment was not a significant predictor of recurrent ISR. Like prior studies on EVBT for PTA, 18, 19 we also did not differentiate between ISR secondary to neointimal hyperplasia and progression of atherosclerosis (eg, based on time to ISR diagnosis or lesion calcification). Although we acknowledge that restenosis lesions secondary to progression of atherosclerosis and neointimal hyperplasia lesions are biologically different, the mechanism of EVBT on delayed vessel wall healing and constrictive remodeling would apply to both types of lesions. 26 Given the limited retrospective nature of the current study, we did not perform a comprehensive cost analysis. We believe that the associated costs of EVBT are in line with other adjunctive therapies that have demonstrated similar or inferior durability. A larger, prospective, matched-control study would help to further address some of our study limitations and better define the future role of EVBT for the treatment of ISR.
CONCLUSIONS
The development of ISR in the lower extremity remains a challenging clinical problem. Our data suggest that the adjunctive use of EVBT after PTA is an effective treatment for ISR in the lower extremity. The use of EVBT obligates close collaboration between the treating interventionalist and a radiation oncologist and a willingness of the treatment team to overcome inherent logistical challenges. Further studies should aim to identify which subset of patients would benefit the most from this promising treatment strategy.
